

Pharmaceutical Market: India A Comprehensive Industry Analysis Q3 2013

<https://marketpublishers.com/r/P946E633C27EN.html>

Date: October 2013

Pages: 161

Price: US\$ 3,400.00 (Single User License)

ID: P946E633C27EN

Abstracts

“Pharmaceutical Market: India, A Competitive Industry Analysis Q3 2013” by Kelly Scientific Publications is a comprehensive report on the pharmaceutical and biotechnology industry in India and its impact on international markets. This report scrutinises top Indian pharmacos and their battle within domestic and international therapeutic markets. The business environment in which they compete is analysed as are key drivers, constraints, challenges and opportunities.

The Indian pharmaceutical market is set to become the eight largest pharma market globally by 2015. This report describes the current therapeutics that are propelling the biopharmaceutical market in India and the main players in the industry. It examines the current economic climate and how India compares to other emerging markets and also evolved markets such as the US and Europe.

This study reveals market figures of the overall Indian pharmaceutical market and sub-markets and is supported by over 330 exhibits. Forecast projections and future growth rates are provided to give the reader a forthcoming perspective of this growing industry.

Current developments relating to patent expirations, government funding, and regulations are discussed. The emerging trends that appear in key sub-markets such as generics, oncology, cardiovascular, diabetes and vaccines are elucidated and analysed.

The study also provides a comprehensive financial and product review of key players in the biopharmaceutical industry in India. Strategic drivers and restraints of this market are revealed and market opportunities and challenges are identified.

In summary, the Indian biopharmaceutical market has huge opportunities for growth.

This industry will significantly affect the international healthcare market and has enormous potential for investment.

The main objectives of this report are:

To comprehensively summarize current developments in the Indian biopharmaceutical industry.

To identify emerging trends in key markets and sub-markets such as biogenerics, cardiology, oncology therapeutics, diabetic care, vaccines and anti-infective agents.

To comprehensive review and analyse financial and product details of key players in the industry

To present market figures of the current Indian biopharmaceutical market value and give forecast projections and growth rates

To identify key drivers and restraints of the Indian biopharmaceutical market

To report and analyse market opportunities and challenges

To identify funding and government sponsorship issues

The reader of this report will gain:

An in-depth understanding of the Indian biopharmaceutical market and it's environment

Current market facts, figures and product lines of key players in the industry

An insight into how generic therapeutics will propagate the Indian biopharmaceutical market

Knowledge of how the Indian biopharma market will integrate into the global healthcare market

Information on key government policies

Data on levels of private and publically funded biopharma studies in India

Strategies on how to adapt and restructure current business models to this industry

This report highlights a number of significant Indian pharmacos and gives details of their operations, products, financials and business strategy. The following companies were chosen for analysis as they have specific advantages that we believe will drive the pharmaceutical industry in India.

Aurobindo Pharma

Bharat Serums and Vaccines Ltd

Biocon Biopharmaceuticals

Cipla

Divis Laboratories

Dr Reddy's Laboratories

Lupin

Mankind Pharma

Panacea Biotech

Piramal Group

Ranbaxy Laboratories

Reliance Life Sciences

Serum Institute of India

Sun Pharmaceuticals

Zydus Cadila

Contents

1.0 SUMMARY

- 1.1 Objectives of Report
- 1.2 Scope of Study
- 1.3 Data Sources and Methodology
- 1.4 Key Findings and Observations
- 1.5 Executive Summary

2.0 EPIDEMIOLOGY AND DISEASE OVERVIEW

- 2.1 Cardiovascular Disease
- 2.2 Infectious Disease
- 2.3 Respiratory Infections
- 2.4 Tuberculosis
- 2.5 HIV
- 2.6 Hepatitis
- 2.7 Typhoid Fever
- 2.8 Dengue Fever
- 2.9 Diabetes
- 2.10 Cancer
- 2.11 Chronic Respiratory Disease- Asthma and COPD

3.0 TWELFTH FIVE YEAR PLAN – A BOOST FOR SCIENTIFIC RESEARCH AND DEVELOPMENT

4.0 ECONOMIC AND BUSINESS ENVIRONMENT

- 4.1 Economic Indicators, Trade Policy and Merchandise and Commercial Trade Statistics
- 4.2 Gross Domestic Product of India, Historic and Projection Analysis
- 4.3 Global and India Economic Outlook 2010-2013
- 4.4 Indian Economic Outlook in Comparison to Advanced Economies (US, Europe)

5.0 INDIAN PHARMACEUTICAL INDUSTRY

- 5.1 Overview
- 5.2 Formulations Market

- 5.3 Active Pharmaceutical Ingredient Market
- 5.4 Biosimilar Market
- 5.5 Contract Research and Manufacturing Service (CRAMS)
- 5.6 Indian Pharmaceutical Industry Market
- 5.7 Evaluation of Market Share by Therapeutic Area
- 5.8 Key Players

6.0 INDIAN PHARMACEUTICAL COMPANY PROFILES AND FINANCIAL DATA

- 6.1 Aurobindo Pharma
- 6.2 Bharat Serums and Vaccines Ltd
- 6.3 Biocon Biopharmaceuticals
- 6.4 Cipla
- 6.5 Divis Laboratories
- 6.6 Dr Reddy's Laboratories
- 6.7 Lupin
- 6.8 Mankind Pharma
- 6.9 Panacea Biotech
- 6.10 Piramal Group
- 6.11 Ranbaxy Laboratories
- 6.12 Reliance Life Sciences
- 6.13 Serum Institute of India
- 6.14 Sun Pharmaceuticals
- 6.15 Zydus Cadila

7.0 SWOT ANALYSIS OF INDIAN PHARMACEUTICAL MARKET

- 7.1 Growth Factors
- 7.2 Strengths of Indian Pharmaceutical Industry
- 7.3 Main Weaknesses
- 7.4 Significant Opportunities within the Indian Pharmaceutical Industry
- 7.5 Threats and Considerations

8.0 COMPANY DIRECTORY AND KEY PEOPLE

- 8.1 Aurobindo Pharma
- 8.2 Bharat Serums and Vaccines Ltd
- 8.3 Biocon Biopharmaceuticals
- 8.4 Cipla

- 8.5 Divis laboratories
- 8.6 Dr Reddy's Laboratories
- 8.7 Lupin
- 8.8 Panacea Biotech
- 8.9 Reliance Life Sciences

9.0 APPENDIX

- 9.1 Comprehensive List of Pharmaceutical Company's in India

List Of Exhibits

LIST OF EXHIBITS

- Exhibit 2.1: Key Statistics: India
- Exhibit 2.2: National Expenditure on Health (Indian Rupee) 2000 – 2011
- Exhibit 2.3: Top Ten Causes of Mortality in India 2008-2030
- Exhibit 2.4: Estimated Number of Deaths Due to Most Prevalent Disease States, India
- Exhibit 2.5: Historic and Projected Death Rates Due to Cardiovascular and Cancer, India 2004-2030
- Exhibit 2.6: Trend of Communicable and Non-Communicable Disease Burden in Developing World 1970-2030
- Exhibit 2.7: Cardiovascular Mortality by Indian State
- Exhibit 2.8: Factors Contributing to High Prevalence of Cardiovascular Disease in India
- Exhibit 2.9: Distribution of Cause of Death in Children under Five, India
- Exhibit 2.10: Global Incidence of Childhood Clinical Pneumonia
- Exhibit 2.11: Global Distribution of Deaths from Pneumonia and other Causes in Children
- Exhibit 2.12: Revised National Tuberculosis Control Program (RNTCP) Statistics 2005-Present
- Exhibit 2.13: Estimated Global Tuberculosis Incidence Rates 2011
- Exhibit 2.14: India TB Statistics by State, Population Covered, Diagnosis, Treatment Relapse and HIV Co-infection
- Exhibit 2.15: Estimated Global HIV Prevalence in New TB Cases 2011
- Exhibit 2.16: Number of MDR-TB Cases Estimated to Occur Among Notified Pulmonary TB Cases 2011
- Exhibit 2.17: Countries That Had Notified of at Least One XDR-TB Case by end of 2011
- Exhibit 2.18: TB Vaccine Development Pipeline 2012
- Exhibit 2.19: HIV Prevalence in India 2004-2009
- Exhibit 2.20: Routes of HIV Transmission in India 2011
- Exhibit 2.21: Global Hepatitis E Virus Endemicity
- Exhibit 2.22: Prevalence of Diabetes by Indian Region
- Exhibit 2.23: Global Prevalence of Undiagnosed Diabetes, 2011
- Exhibit 2.24: Incidence and Mortality Rates for Top Sixteen Cancers in India – Both Sexes
- Exhibit 2.25: Prevalence of Cancer Cases and Deaths in India, Male and Female
- Exhibit 2.26: Incidence and Mortality Rates for Top Sixteen Cancers in India - Men
- Exhibit 2.27: Incidence and Mortality Rates for Top Sixteen Cancers in India – Women
- Exhibit 2.28: Percentage Incidence Distribution of the most Frequent Cancers in India,

Both Sexes

Exhibit 2.28: Percentage Mortality Distribution of the most Frequent Cancers in India, Both Sexes

Exhibit 2.29: Five Year Prevalence and Incidence of Top Twenty Cancer's in India

Exhibit 2.30: Mortality Rate Attributable to Chronic Obstructive Pulmonary Disease Globally

Exhibit 3.1: India's Twelve Year Plan – Key Points in Relation to Science Research and Development

Exhibit 3.2: Budget for Specific Scientific Departments under India's Twelfth Five Year Plan

Exhibit 4.1: World Trade Organisation Basic Indicators on India

Exhibit 4.2: World Trade Organisation Trade Policy of India

Exhibit 4.3: World Trade Organisation Merchandise Trade Statistics: India

Exhibit 4.4: World Trade Organisation Commercial Services Trade Statistics: India

Exhibit 4.5: World Trade Organisation Industrial Property Statistics: India

Exhibit 4.6: India GDP Figures 2011-2018

Exhibit 4.7: India Health Expenditure as a Percentage of GDP 2000-2010

Exhibit 4.8: Global, Emerging Market and Developing Countries Economic Growth Change 2010-2013

Exhibit 4.9: Global, Emerging Market and Developing Countries and India Economic Growth Change 2010- 2013

Exhibit 4.10: Global, Emerging Market and Developing Countries and Russia Economic Growth Change 2010-2013

Exhibit 4.11: Global, Emerging Market and Developing Countries and Russia Economic Growth Change 2010-2013

Exhibit 4.12: Global, Emerging Market and Developing Countries and Brazil Economic Growth Change 2010-2013

Exhibit 4.13: Global, US and Germany Economic Growth 2010-2013

Exhibit 4.14: US and UK Gross Domestic Product per capita Forecast 2010-2017

Exhibit 4.15: Global, France and Italy Economic Growth 2010-2013

Exhibit 4.16: France, Germany and Italy Gross Domestic Product per capita Forecast 2010-2017

Exhibit 4.17: Global, UK and Spain Economic Growth 2010-2013

Exhibit 4.18: Global, Japan and Canada Economic Growth 2010-2013

Exhibit 4.19: India, Brazil and China Gross Domestic Product per capita Forecast 2010-2017

Exhibit 5.1: Four Major Areas of the Indian Pharmaceutical Industry

Exhibit 5.2: Indian Pharmaceutical Industry IPM and Exports 2003-2015

Exhibit 5.3: Indian Pharmaceutical Industry Bulk Drug Exports 2003-2015

- Exhibit 5.4: Indian Pharmaceutical Industry Formulation Exports 2003-2015
- Exhibit 5.5: Indian Pharmaceutical Industry Domestic Formulations 2003-2015
- Exhibit 5.6: Geographic Distribution of India's Active Pharmaceutical Ingredient Exports, 2012
- Exhibit 5.7: Current Trends of the Global Biosimilar Market
- Exhibit 5.8: Main Therapeutic Areas of the Future Biosimilar Market
- Exhibit 5.9: Market Share (\$ Billions) of Contract Manufacturing and Research within Indian CRAMS Industry
- Exhibit 5.10: Market Share (Percentage) of Contract Manufacturing and Research within Indian CRAMS Industry
- Exhibit 5.11: Indian Contract Research and Manufacturing Services (CRAMS) Market 2010-2015
- Exhibit 5.12: Leading Players of the Indian Pharmaceutical Market
- Exhibit 5.13: India - Significant Economic Indicators
- Exhibit 5.14: Positive Factors Influencing the Indian Pharmaceutical Market
- Exhibit 5.15: Quantitative Market Share of Acute and Chronic Therapy in India, 2012
- Exhibit 5.16: Multinational Company Penetration into Indian Pharmaceutical Market 2011
- Exhibit 5.17: Key Factors Influencing Leading Player Position in India Pharma Market
- Exhibit 5.18: Indian Pharmaceutical Market Share (%) by Therapeutic Area
- Exhibit 5.19: Top Five Fastest Growing Indian Pharma Market Segments, 2012
- Exhibit 5.20: Top Five Emerging Opportunities within the Indian Pharmaceutical Market
- Exhibit 5.21: Top Pharmaceutical Companies within the Indian Pharmaceutical Market by Market Share and Revenue
- Exhibit 5.22: Percentage Market Share of Leading Players in the Indian Pharmaceutical Market
- Exhibit 5.23: Revenue Reported from Leading Players of Indian Pharmaceutical Market 2012
- Exhibit 6.1: Aurobindo Pharma Therapeutic Areas of Interest
- Exhibit 6.2: Aurobindo Pharma Formulation Unit Accreditation
- Exhibit 6.3: Aurobindo Pharma Range of Anti-Infective Formulations
- Exhibit 6.4: Aurobindo Pharma Therapeutic Areas of Interest
- Exhibit 6.5: Aurobindo Pharma Antiretroviral Therapeutic Product Portfolio
- Exhibit 6.6: Aurobindo Pharma Antiosteoporotic Therapeutic Product Portfolio
- Exhibit 6.7: Aurobindo Pharma Antihypertensive Therapeutic Product Portfolio
- Exhibit 6.8: Aurobindo Pharma Antiasthmatic Therapeutic Product Portfolio
- Exhibit 6.9: Aurobindo Pharma Beta-Lactam-Antibiotic Product Portfolio
- Exhibit 6.10: Aurobindo Pharma Anti Erectile Dysfunction Product Portfolio
- Exhibit 6.11: Aurobindo Pharma Antiosteoporotic Product Portfolio

- Exhibit 6.12: Aurobindo Pharma Alzheimer's Product Portfolio
- Exhibit 6.13: Aurobindo Pharma Antibiotic Product Portfolio
- Exhibit 6.14: Aurobindo Pharma Antidepressant Product Portfolio
- Exhibit 6.15: Aurobindo Pharma Antidiabetic Product Portfolio
- Exhibit 6.16: Aurobindo Pharma Antiemetic Product Portfolio
- Exhibit 6.17: Aurobindo Pharma Antiepileptic Therapeutic Portfolio
- Exhibit 6.18: Aurobindo Pharma Cardiovascular Therapeutic Portfolio
- Exhibit 6.19: Aurobindo Pharma CNS Therapeutic Portfolio
- Exhibit 6.20: Aurobindo Pharma Pain Management Therapeutic Portfolio
- Exhibit 6.21: Aurobindo Pharma Consolidated Revenue 2009-2012
- Exhibit 6.22: Aurobindo Pharma Subsidiary Companies
- Exhibit 6.23: Aurobindo Pharma Long Term Growth Strategies
- Exhibit 6.24: Bharat Serums and Vaccines Significant Milestones
- Exhibit 6.25: Bharat Serums and Vaccines Range of Products
- Exhibit 6.26: Bharat Serums and Vaccines Plasma Serum Product Portfolio
- Exhibit 6.27: Bharat Serums and Vaccines Monoclonal Antibody Product Portfolio
- Exhibit 6.28: Bharat Serums and Vaccines Equine Antitoxin and Serum Product Portfolio
- Exhibit 6.29: Bharat Serums and Vaccines Cardiovascular Product Portfolio
- Exhibit 6.30: Bharat Serums and Vaccines Anti-microbial Product Portfolio
- Exhibit 6.31: Bharat Serums and Vaccines Anti-fungal Product Portfolio
- Exhibit 6.32: Bharat Serums and Vaccines Anaesthesia Product Portfolio
- Exhibit 6.33: Bharat Serums and Vaccines Hormone Product Portfolio
- Exhibit 6.34: Biocon Biopharmaceuticals Business Outline
- Exhibit 6.35: Biocon Biopharmaceuticals Five Key Business Areas
- Exhibit 6.36: Biocon Biopharmaceuticals Subsidiary Companies
- Exhibit 6.37: Biocon Biopharmaceuticals Important Milestones
- Exhibit 6.38: Biocon Biopharmaceuticals Active Pharmaceutical Ingredients (APIs) Product Areas
- Exhibit 6.39: Biocon Biopharmaceuticals Active Biological Product Areas
- Exhibit 6.40: Biocon Biopharmaceuticals Diabetes Branded Formulations
- Exhibit 6.41: Biocon Biopharmaceuticals Oncology Branded Therapeutics
- Exhibit 6.42: Biocon Biopharmaceuticals Nephrology Branded Therapeutics
- Exhibit 6.43: Biocon Biopharmaceuticals Cardiology Branded Therapeutics
- Exhibit 6.44: Biocon Biopharmaceuticals Comprehensive Care Branded Therapeutics
- Exhibit 6.45: Biocon Biopharmaceuticals Immunotherapy Branded Therapeutics
- Exhibit 6.46: Biocon Biopharmaceuticals BioTherapy Branded Therapeutics
- Exhibit 6.47: Biocon Biopharmaceuticals – Syngene Service Platform
- Exhibit 6.48: Biocon Biopharmaceuticals – Clinigene Service Platform

- Exhibit 6.49: Biocon Biopharmaceuticals Revenue 2008-2012
- Exhibit 6.50: Biocon Biopharmaceuticals Revenue 2008-2012
- Exhibit 6.51: Biocon Biopharmaceuticals Profits from Operations 2008-2012
- Exhibit 6.52: Biocon Biopharmaceuticals Profits from Operations 2008-2012
- Exhibit 6.53: Cipla Important Milestones
- Exhibit 6.54: Cipla Main Therapeutics Areas of Interest
- Exhibit 6.55: Cipla Export Market Share FY2011-2012
- Exhibit 6.56: Cipla Sales and Other Income Exhibits 2003-2012
- Exhibit 6.57: Cipla Profit after Tax Exhibits 2003-2012
- Exhibit 6.58: Cipla Significant Product Launches During FY 2011-2012
- Exhibit 6.59: Cipla Significant Active Pharmaceutical Ingredient Commercialisation Launches During FY 2011-2012
- Exhibit 6.60: Divis Laboratories Important Milestones
- Exhibit 6.61: Divis Laboratories Product Category Portfolio
- Exhibit 6.62: Divis Laboratories Product List
- Exhibit 6.63: Divis Laboratories Income From Operations 2006-2012
- Exhibit 6.64: Divis Laboratories Future Pipeline Portfolio
- Exhibit 6.65: Dr Reddy's Therapeutic Areas of Interest
- Exhibit 6.66: Dr Reddy's Laboratories – Important Milestones
- Exhibit 6.67: Dr Reddy's Labs Top Active Pharmaceutical Ingredients
- Exhibit 6.68: Dr Reddy's Labs Top Brands in India
- Exhibit 6.69: Dr Reddy's Laboratories Annual Revenue Exhibits 2003-2012
- Exhibit 6.70: Dr Reddy's Laboratories Historical Revenue Exhibits 2003-2012 (Global)
- Exhibit 6.71: Dr Reddy's Laboratories Geographical Revenue Percentage 2012
- Exhibit 6.72: Dr Reddy's Key Brand Revenue in Russia 2011-2012
- Exhibit 6.73: Dr Reddy's Key Brand Revenue in India 2011-2012
- Exhibit 6.74: Dr Reddy's Therapeutic Agents and Classes undergoing Clinical Trials
- Exhibit 6.75: Lupin Significant Milestones
- Exhibit 6.76: Lupin Ltd Formulations Product Portfolio
- Exhibit 6.77: Lupin Ltd Active Pharmaceutical Ingredient Product Portfolio
- Exhibit 6.78: Lupin Ltd Formulation and Active Pharmaceutical Ingredient Business Contribution
- Exhibit 6.79: Lupin Ltd Formulations and Active Pharmaceutical Ingredient Exports 2006-2012
- Exhibit 6.80: Lupin Ltd Formulation and Active Pharmaceutical Ingredient Revenue Contribution 2012
- Exhibit 6.81: Lupin Ltd Geographic Breakdown of Revenue 2012
- Exhibit 6.82: Lupin Ltd Net Global Sales 2008-2012
- Exhibit 6.83a: Lupin Ltd Profit Before Tax 2008-2012

- Exhibit 6.83b: Lupin Ltd Formulation Sales 2006-2012 Indian Market
- Exhibit 6.84: Lupin Ltd Top Product Brands in the Indian Market and Ranking
- Exhibit 6.85: Lupin Ltd Therapeutic Area Growth Increase in Comparison to Overall Market Growth
- Exhibit 6.86: Lupin Pharma Key Products and Rank in the Indian Market
- Exhibit 6.87: Lupin Respira Key Products and Rank in the Indian Market
- Exhibit 6.88: Lupin Endeavour Key Products and Rank in the Indian Market
- Exhibit 6.89: Lupin Maxter Key Products and Rank in the Indian Market
- Exhibit 6.90: Lupin Pinnacle CVS Key Products and Rank in the Indian Market
- Exhibit 6.90: Lupin Diabetes Care Key Products and Rank in the Indian Market
- Exhibit 6.91: Lupin Mindvision Key Products and Rank in the Indian Market
- Exhibit 6.92: Lupin Ikonc Key Products and Rank in the Indian Market
- Exhibit 6.93: Lupin Pharmaceuticals Formulation Sales US Market 2007-2012
- Exhibit 6.94: Lupin Ltd Performance in Top Five Generic Pharmaceutical Companies in the US Market
- Exhibit 6.95: Lupin Ltd Percentage Market Share within US Generics Market
- Exhibit 6.96: Lupin Ltd (Kyowa Pharmaceutical) Sales in Japanese Market 2008-2012
- Exhibit 6.97: Lupin Ltd Division of Sales by Therapeutic Area
- Exhibit 6.98: Lupin Ltd Advanced Drug Delivery System Platform Portfolio
- Exhibit 6.99: Lupin Ltd Research and Development Areas of Expertise
- Exhibit 6.100: Mankind Pharma Company Divisions
- Exhibit 6.101: Mankind Pharma Key Milestones
- Exhibit 6.102: Mankind Pharma Therapeutic Areas of Interest
- Exhibit 6.103: Mankind Pharma Prescription Product Areas
- Exhibit 6.104: Mankind Pharma Top Ten Brands
- Exhibit 6.105: Mankind Pharma Diabetic Product Brands
- Exhibit 6.106: Mankind Pharma Hyperthyroidism Product Brands
- Exhibit 6.107: Mankind Pharma Cough Product Brands
- Exhibit 6.108: Mankind Pharma Malaria Product Brands
- Exhibit 6.109: Mankind Pharma Migraine Product Brands
- Exhibit 6.110: Mankind Pharma Anti-viral Product Brands
- Exhibit 6.111: Mankind Pharma Steroid Product Brands
- Exhibit 6.112: Mankind Pharma Dermatology Product Brands
- Exhibit 6.113: Mankind Pharma Ophthalmology Product Brands
- Exhibit 6.114: Mankind Pharma Gynaecology Product Brands
- Exhibit 6.115: Mankind Pharma Antibiotic Product Brands
- Exhibit 6.116: Mankind Pharma Asthmatic Product Brands
- Exhibit 6.117: Panacea Biotech Strategic Business Unit Structure
- Exhibit 6.118: Panacea Biotech Therapeutic Areas of Interest

- Exhibit 6.119: Panacea Biotech Leading Brands in India
- Exhibit 6.120: Panacea Biotech Pain Management Therapy Portfolio
- Exhibit 6.121: Panacea Biotech Diacar Alpha and Diacar Delta SBU Oral Hypoglycemic Product Range
- Exhibit 6.122: Panacea Biotech Diacar Alpha and Diacar Delta SBU Cardiovascular Product Range
- Exhibit 6.123: Panacea Biotech Vaccine Portfolio
- Exhibit 6.124: Panacea Biotech Diabetes Management Portfolio
- Exhibit 6.125: Panacea Biotech Anti-Osteoporotic Portfolio
- Exhibit 6.126: Panacea Biotech Antipyretic, Anti-inflammatory and Analgesic Portfolio
- Exhibit 6.127: Panacea Biotech Renal Disease Management Portfolio
- Exhibit 6.128: Panacea Biotech Gastro Intestinal Product Portfolio
- Exhibit 6.129: Panacea Biotech Constipation Product Portfolio
- Exhibit 6.130: Panacea Biotech Tuberculosis Product Portfolio
- Exhibit 6.131: Panacea Biotech Cough/Cold Product Portfolio
- Exhibit 6.132: Panacea Biotech Brand Standing and Market Share (India) - Diabetes and Cardiac Care
- Exhibit 6.133: Panacea Biotech Brand Standing and Market Share (India) - Pain Management
- Exhibit 6.134: Panacea Biotech Brand Standing and Market Share (India) – Tuberculosis Treatment
- Exhibit 6.135: Panacea Biotech Brand Standing and Market Share (India) – Gastrointestinal Treatment
- Exhibit 6.136: Panacea Biotech Brand Standing and Market Share (India) – Anti-Haemorrhoidal
- Exhibit 6.137: Panacea Biotech Brand Standing and Market Share (India) – Penicillins
- Exhibit 6.138: Panacea Biotech Current Patents for Licencing
- Exhibit 6.139: Panacea Biotech Net Turnover 2002-2012
- Exhibit 6.140: Panacea Biotech Net Turnover 2002-2012
- Exhibit 6.141: Panacea Biotech Geographic Distribution of Sales, 2010-2012
- Exhibit 6.142: Panacea Biotech Geographic Distribution of Sales, 2010-2012
- Exhibit 6.143: Key Milestones in Piramal Group History
- Exhibit 6.144: Piramal Distribution of Sales (Percentage) 2012
- Exhibit 6.145: Piramal Distribution of Pharma Solutions Domestic and International Sales 2012
- Exhibit 6.146: Piramal Pharma Solutions Sales from Domestic and International Assets 2011-2012
- Exhibit 6.147: Piramal Oncology Therapeutic Pipeline
- Exhibit 6.148: Piramal Inflammation Therapeutic Pipeline

- Exhibit 6.149: Piramal Diabetic and Metabolic Disease Therapeutic Pipeline
- Exhibit 6.150: Piramal Infectious Disease Therapeutic Pipeline
- Exhibit 6.151: Ranbaxy Laboratories – Therapeutic Markets of Interest
- Exhibit 6.152: Ranbaxy’s Oral Platform Technologies using a Novel Drug Delivery System
- Exhibit 6.153: Ranbaxy Laboratories - Top Ten Therapeutics
- Exhibit 6.154: Ranbaxy Key Merger and Acquisition Activity since 2006
- Exhibit 6.155: List of Ranbaxy Subsidiary Companies
- Exhibit 6.156: Ranbaxy – Future Therapeutic Areas
- Exhibit 6.157: Ranbaxy Global Sales by Geographical Region
- Exhibit 6.158: Ranbaxy Global Sale Figures by Geographical Region
- Exhibit 6.159: Ranbaxy Geographical Market Share Percentage
- Exhibit 6.160: Ranbaxy Developed and Emerging Market Share
- Exhibit 6.161: Ranbaxy Sales Figures, USA and Canada
- Exhibit 6.162: Ranbaxy Sales Figures, Europe
- Exhibit 6.163: Ranbaxy Top Sellers in India
- Exhibit 6.164: Ranbaxy Sales Figures, India
- Exhibit 6.165: Ranbaxy Market Share of Top Therapeutics, India
- Exhibit 6.166: Ranbaxy Launches by Geographical Region
- Exhibit 6.167: Reliance Life Sciences Biopharmaceutical Product Areas
- Exhibit 6.168: Reliance Life Sciences Pharmaceutical Product Areas
- Exhibit 6.169: Reliance Life Sciences Clinical Research Services
- Exhibit 6.170: Reliance Life Sciences Regenerative Medicine Product Areas
- Exhibit 6.171: Reliance Life Sciences Molecular Medicine Product Areas
- Exhibit 6.172: Reliance Life Science Plasma Protein Product Portfolio
- Exhibit 6.173: Reliance Life Science Biosimilar Product Portfolio
- Exhibit 6.174: Reliance Life Science Pharmaceutical Product Portfolio
- Exhibit 6.175: Reliance Life Science Regenerative Medicine Product Portfolio
- Exhibit 6.176: Reliance Life Science R&D Activities
- Exhibit 6.177: Serum Institute of India Significant Milestones
- Exhibit 6.178a: Serum Institute of India Manufactured Products
- Exhibit 6.178b: Serum Institute of India Marketed Products
- Exhibit 6.179: Serum Institute of India Exported Products
- Exhibit 6.180: Serum Institute of India Product Pipeline
- Exhibit 6.181: Sun Pharmaceuticals – Important Milestones
- Exhibit 6.182: Sun Pharmaceuticals Revenue Stream 2011-2012 (percentage)
- Exhibit 6.183: Sun Pharmaceutical Revenue Stream 2011-2012 (\$ Millions)
- Exhibit 6.184: Sun Pharmaceuticals Percentage Breakdown of Therapeutic Area Sales 2012

- Exhibit 6.185: Sun Pharmaceuticals Top Ten Branded Generics in India
- Exhibit 6.186: Sun Pharmaceuticals Number of Drug Approvals by Therapeutic Area
- Exhibit 6.187: Zydus Research Centre Speciality Areas of Research
- Exhibit 6.188: Zydus Cadila Vaccine R&D Areas of Research
- Exhibit 6.189: Zydus Cadila Global 'Beyond the Billion' Business Development Strategy
- Exhibit 6.190: Zydus Cadila Top Formulation Brands in the Indian Market
- Exhibit 6.191: Zydus Cadila New Molecular Entities in Development Pipeline
- Exhibit 6.192: Zydus Cadila Biosimilar Therapeutics in Development Pipeline
- Exhibit 6.193: Zydus Cadila Indian Formulation Market Distribution (%) by Therapeutic Area 2012
- Exhibit 6.194: Zydus Cadila Gross Sales 2006-2012
- Exhibit 6.195: Zydus Cadila List of Subsidiary Companies
- Exhibit 6.196: Zydus Cadila Key Acquisitions 1995-2012
- Exhibit 6.197: Zydus Cadila Research and Development Areas of Interest
- Exhibit 7.1: Main Growth Factors of the Indian Pharmaceutical Market
- Exhibit 7.2: Indian Health Insurance Coverage Statistics 2010-2020
- Exhibit 7.3: Strengths of the Indian Pharmaceutical Market
- Exhibit 7.4: Weaknesses of the Indian Pharmaceutical Market
- Exhibit 7.5: Opportunities within the Indian Pharmaceutical Market
- Exhibit 7.6: Threats to the Indian Pharmaceutical Market
- Exhibit 8.1: Aurobindo Pharma Key Contact Details
- Exhibit 8.2: Aurobindo Pharma Board of Directors and Key Personnel
- Exhibit 8.3: Bharat Serums and Vaccines Ltd General Contact Details
- Exhibit 8.4: Bharat Serums and Vaccines Ltd Board of Directors
- Exhibit 8.5: Biocon Biopharmaceuticals Key Contact Details
- Exhibit 8.6: Biocon Biopharmaceuticals Board of Directors
- Exhibit 8.7: Biocon Biopharmaceuticals Key Management Team
- Exhibit 8.8: Cipla Executive Directors
- Exhibit 8.9: Cipla Non-Executive/Independent Directors
- Exhibit 8.10: Cipla Corporate Contact Details
- Exhibit 8.11: Divis Laboratories Key Contact Details
- Exhibit 8.12: Divis Laboratories Key People
- Exhibit 8.13: Dr Reddy's Laboratories Contact Information
- Exhibit 8.14: Dr Reddy's Laboratories Key People
- Exhibit 8.15: Dr Reddy's Laboratories Board of Directors
- Exhibit 8.16: Dr Reddy's Audit Committee Members
- Exhibit 8.17: Dr Reddy's Nomination, Governance & Compensation Committee Members

- Exhibit 8.18: Dr Reddy's Risk Management Committee Members
- Exhibit 8.19: Dr Reddy's Science, Technology and Operations Committee Members
- Exhibit 8.20: Dr Reddy's Shareholders' Grievance Committee Members
- Exhibit 8.21: Dr Reddy's Investment Committee Members
- Exhibit 8.22: Dr Reddy's Management Committee Members
- Exhibit 8.23: Lupin Board of Directors
- Exhibit 8.24: Lupin Key Management Players
- Exhibit 8.25: Lupin Ltd General Contact Details
- Exhibit 8.26: Panacea Biotech – Whole Time Directors
- Exhibit 8.27: Panacea Biotech – Independent Directors
- Exhibit 8.28: Panacea Biotech – Investor Contact Details
- Exhibit 8.29: Panacea Biotech – General Contact Details
- Exhibit 8.30: Reliance Life Sciences – General Contact Details

COMPANIES MENTIONED

Aurobindo Pharma
Bharat Serums and Vaccines Ltd
Biocon Biopharmaceuticals
Cipla
Divis Laboratories
Dr Reddy's Laboratories
Lupin
Mankind Pharma
Panacea Biotech
Piramal Group
Ranbaxy Laboratories
Reliance Life Sciences
Serum Institute of India
Sun Pharmaceuticals
Zydus Cadila

About

Today, India is the second largest country and is populated by more than 1.2 billion. By 2050, it is estimated that the population will have grown to between 1.6-1.8 billion and so key investments and strategies to exploit this growing market is paramount. India's potential as a key player in the pharma market is significant.

The population of India over 60 years old is forecast to reach 300 million by 2050. This is a 17% increase from 77 million in 2001. Noncommunicable diseases (NCDs) such as heart disease, stroke, cancer, chronic respiratory disease, diabetes, mental health issues, vision and hearing difficulties will all increase in incidence with this population growth and put pressure on health services. According to the World Health Organisation (WHO), 80% of adult deaths are due to NCDs in urban centres and 60% of deaths in rural areas.

Over 20% of the Indian population are currently suffering from a chronic disease and 10% have comorbidities. Chronic diseases cause 50% of all deaths in India. Infectious and parasitic diseases are a significant contributor, as are cardiovascular diseases, respiratory conditions, cancer and diabetes.

According to a study by Patel et al in The Lancet, almost 75% of all deaths in India will be due to a chronic disease in 2030.

Cancer fatalities will rise from 730,000 in 2004 to 1.5 million in 2030.

Cardiovascular deaths will increase from 2.7 million in 2004 to 4 million in 2030.

Coronary heart disease deaths will increase from 7.1 million in 2004 to 17.9 million in 2030.

I would like to order

Product name: Pharmaceutical Market: India A Comprehensive Industry Analysis Q3 2013

Product link: <https://marketpublishers.com/r/P946E633C27EN.html>

Price: US\$ 3,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P946E633C27EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970